It’s always fascinating to listen to two of the recognized experts and leading clinicians in Cushing’s disease discuss their experiences with the disease and patients. In this Live Talk session, Pituitary World New’s innovative program for education and awareness, Dr. Kevin Yuen and Dr. Lewis Blevins bring an intimate, revealing look at their approaches to Cushing’s disease and syndrome. The discussion focuses on their experiences and how they think about their patients, and the options they have available for treatment. Listen and learn their views on each available drug to treat the disease and their rationale for recommending treatment options. And don’t miss the discussion on access to those medications, including insurance coverage issues, towards the end of the session. Enjoy!
On Cushing’s Day, we share Sharmyn McGraw’s blog on her journey with the disease. From her Blog – “Now twenty-one years in remission from a pituitary adenoma tumor, Sharmyn McGraw, patient advocate, author, artist, and
Recordati Rare Diseases, a company dedicated to creating needed therapies for extremely rare and devastating diseases, had an excellent idea of approaching their new educational resource website for Cushing’s disease; they asked patients with Cushing’s
An informal discussion of Cushing’s disease issues from cases, articles, and experiences with patients.
During these trying times, work continues, even at a faster pace, for new drugs and therapies for pituitary patients. From the J D Faccinetti, co-founder – We recently caught up with Crinetics Pharmaceuticals chairman Dr.
Grzegorz Rosiak, M.D., an interventional radiologist from Warsaw Medical University, sends us a recently published article, “Percutaneous Adrenal Gland Thermal Ablation,” an alternative Cushing syndrome treatment. You can read more about thermal ablation of the adrenal gland
With new advances in the Cushings space, we asked Dr. Maria Fleseriu, Professor of Medicine and Neurological Surgery and Director of the Pituitary Center at Oregon Health and Science University in Portland, Oregon, USA, to give us
In a recent press release, Recordati Rare Diseases announced the results from a Phase III study of Isturisa® (Osilodrostat) published in Lancet Diabetes and Endocrinology. “The exciting data, published today, underscore the efficacy and safety
From Leslie Edwin, President of CSRF and PWN Contributor – On June 18, 2020, online medical journal The Lancet Diabetes and Endocrinology published a report about the association between high cortisol and death rate with COVID-19.
In this engaging podcast about the diagnosis of Cushing’s syndrome, Pituitary Worlds News co-founder and Medical Director, California Center for Pituitary Disorders at UCSF Professor of Clinical Medicine and Clinical Neurological Surgery, Dr. Lewis Blevins
This is a series of urgent clinical guidance documents on the management of endocrine conditions in the time of COVID-19. This clinical guidance document underwent expedited open peer review by Jérôme Bertherat (Paris, France), André